ライフサイエンスコーパス: non-small-cell

1 eated patients with renal cell carcinoma and non-small-cell carcinoma.

2 erapy for patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC).

3 (n = 4), and management of clinical stage I non-small cell lung cancer (n = 1) were developed and mo

4 econdary to melanoma (n = 29 with 75 BMs) or non-small cell lung cancer (n = 11 with 32 BMs) treated

5 ependent cohort of patients with early-stage non-small cell lung cancer (N = 14), where the therapeut

6 (n = 143), small cell lung cancer (n = 151), non-small cell lung cancer (n = 225), gastrointestinal c

7 Cultured human non-small cell lung cancer (NSCLC) A549 cells take up th

8 Somatic in vivo editing can model non-small cell lung cancer (NSCLC) adenocarcinomas, enab

9 ocus exclusively on the role of NF-kappaB in non-small cell lung cancer (NSCLC) and discuss its contr

10 In non-small cell lung cancer (NSCLC) and prostate cancers,

11 2) whose silencing sensitized the human A549 non-small cell lung cancer (NSCLC) and SW620 colorectal

12 sults where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to perso

13 Tumors of human non-small cell lung cancer (NSCLC) are heterogeneous but

14 o the development of targeted therapies with non-small cell lung cancer (NSCLC) being a paradigm for

15 ceptor (EGFR) signaling is effective in some non-small cell lung cancer (NSCLC) but not in triple-neg

16 to the EGFR TKI osimertinib (AZD9291) in the non-small cell lung cancer (NSCLC) cell line H1975, whic

17 we applied this approach to a KRAS-dependent non-small cell lung cancer (NSCLC) cell line, H23-KRAS(G

18 A large panel of non-small cell lung cancer (NSCLC) cell lines (73 of 77)

19 s from central carbon metabolism, in over 80 non-small cell lung cancer (NSCLC) cell lines cultured u

20 ived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enha

21 Validation data: One set of public non-small cell lung cancer (NSCLC) data.

22 ibution of platinum at the cellular level in non-small cell lung cancer (NSCLC) explant models after

23 eneration of NADPH; however, its function in non-small cell lung cancer (NSCLC) has not been establis

24 ty studies in patients with locally advanced non-small cell lung cancer (NSCLC) have been limited by

25 Non-small cell lung cancer (NSCLC) have been reported to

26 Smoker patients with non-small cell lung cancer (NSCLC) have poorer prognosis

27 KRAS-mutant non-small cell lung cancer (NSCLC) is a major lung cance

28 A subset of non-small cell lung cancer (NSCLC) is driven by amplific

29 Non-small cell lung cancer (NSCLC) is known to have poor

30 the EGFR inhibitor (EGFRi), osimertinib, in non-small cell lung cancer (NSCLC) is limited by acquire

31 Non-small cell lung cancer (NSCLC) is often characterize

32 Non-small cell lung cancer (NSCLC) is the deadliest form

33 Non-small cell lung cancer (NSCLC) is the leading cause

34 Non-small cell lung cancer (NSCLC) is the most frequent

35 PET after curative-intent chemoradiation for non-small cell lung cancer (NSCLC) is unknown.

36 y optimizing rheological parameters to print non-small cell lung cancer (NSCLC) patient derived xenog

37 This platform was also tested using non-small cell lung cancer (NSCLC) patient samples, wher

38 (2019-2021), the majority (63%) of stage III non-small cell lung cancer (NSCLC) patients are prescrib

39 Methods: Seventy-five non-small cell lung cancer (NSCLC) patients planned for

40 DG PET/CT radiomics signature in early-stage non-small cell lung cancer (NSCLC) patients treated with

41 This study examines a population of non-small cell lung cancer (NSCLC) patients with synchro

42 cells isolated from tumor tissue samples of non-small cell lung cancer (NSCLC) patients, and identif

43 espect to (18)F-FDG PET response criteria in non-small cell lung cancer (NSCLC) patients.

44 EGFR gene is commonly observed in tumors of non-small cell lung cancer (NSCLC) patients.

45 rns of local versus distant recurrences in a non-small cell lung cancer (NSCLC) population with mutat

46 and immunohistochemistry (IHC) on 8 pairs of non-small cell lung cancer (NSCLC) primary tumors and ma

47 oding RNA (lncRNA) that are involved in male non-small cell lung cancer (NSCLC) radiation sensitivity

48 at majority of miR-21-5p isolated from human non-small cell lung cancer (NSCLC) tissue possesses 3'-t

49 could potentiate the action of cisplatin in non-small cell lung cancer (NSCLC) treatment.

50 cribed RNA aptamer (trans-RA16) that targets non-small cell lung cancer (NSCLC) was previously identi

51 macrophages and monocytes from patients with non-small cell lung cancer (NSCLC) where c-MAF is overex

52 developed for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR-mutant tumo

53 Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoin

54 esses the growth of subcutaneously implanted non-small cell lung cancer (NSCLC) xenografts and nearly

55 In non-small cell lung cancer (NSCLC), accumulation of anti

56 tumor types, including subsets of melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyro

57 ly prevalent in certain tumor types, notably non-small cell lung cancer (NSCLC), and associated with

58 ins have significantly advanced treatment of non-small cell lung cancer (NSCLC), but protein level qu

59 radiotherapy is an option for patients with non-small cell lung cancer (NSCLC), distinguishing betwe

60 While KRAS mutations are common in non-small cell lung cancer (NSCLC), effective treatments

61 beta (ERbeta) may impact the progression of non-small cell lung cancer (NSCLC), its linkage to alter

62 chemotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resist

63 the division of labor between YAP and TAZ in non-small cell lung cancer (NSCLC), the most common hist

64 rt a critical role for proline catabolism in non-small cell lung cancer (NSCLC).

65 er cell integrity during clonal evolution in non-small cell lung cancer (NSCLC).

66 g the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC).

67 gly utilized to treat solid tumors including non-small cell lung cancer (NSCLC).

68 lower lobe is related with worse outcome of non-small cell lung cancer (NSCLC).

69 in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

70 death-1 blockers is a promising modality for non-small cell lung cancer (NSCLC).

71 poor survival particularly in patients with non-small cell lung cancer (NSCLC).

72 als for different types of cancer, including non-small cell lung cancer (NSCLC).

73 improve accuracy of pulmonary resection for non-small cell lung cancer (NSCLC).

74 t inhibitors, respectively, in patients with non-small cell lung cancer (NSCLC).

75 FR) is a major player in the pathogenesis of non-small cell lung cancer (NSCLC).

76 inhibitors and immune checkpoint blockade in non-small cell lung cancer (NSCLC).

77 xicity anti-cancer agent imperialine against non-small cell lung cancer (NSCLC).

78 o assign effective personalized therapies in non-small cell lung cancer (NSCLC).

79 form has been applied to advanced metastatic non-small cell lung cancer (NSCLC).

80 for the response to these agents in treating non-small cell lung cancer (NSCLC).

81 utic approach for several cancers, including non-small cell lung cancer (NSCLC).

82 expression program of de novo lipogenesis in non-small cell lung cancer (NSCLC).

83 FR in treatment-naive patients with advanced non-small cell lung cancer (NSCLC).

84 rinodular regions of nodules can distinguish non-small cell lung cancer adenocarcinomas from benign g

85 r-extracted imaging) features to distinguish non-small cell lung cancer adenocarcinomas from granulom

86 as clinical therapy in malignancies such as non-small cell lung cancer and has shown good results in

87 the recent advances in precision therapy for non-small cell lung cancer and their implications on ima

88 e the progression of pre-invasive lesions in non-small cell lung cancer are poorly understood.

89 Using non-small cell lung cancer as a case study, we show that

90 diotherapy for nonoperative locally advanced non-small cell lung cancer between 2004 and 2014.

91 cle checkpoint kinase, CHK1, in a variety of non-small cell lung cancer cell lines using CRISPR-media

92 fic ligands that bind a CSC subpopulation of non-small cell lung cancer cells (defined by Aldefluor p

93 fective evolutionary games in co-cultures of non-small cell lung cancer cells that are sensitive and

94 We discovered that a subset of non-small cell lung cancer cells underwent a gradually p

95 CNOT3 suppresses proliferation of A549 human non-small cell lung cancer cells with enhanced mRNA stab

96 a novel mRNA degradation target of CNOT3 in non-small cell lung cancer cells.

97 ty to drive tumor invasion and metastasis of non-small cell lung cancer cells.

98 ells and of treatment with erlotinib of PC-9 non-small cell lung cancer cells.

99 the growth of K-Ras-addicted pancreatic and non-small cell lung cancer cells.

100 sing a 96-well automated workflow in a pilot non-small cell lung cancer classification study.

101 conclusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras

102 In a genetically engineered mouse model of non-small cell lung cancer driven by K-Ras G12D and p53

103 this has not been validated in patients with non-small cell lung cancer due to the difficulty to obta

104 F-BMS-986192 in patients with advanced-stage non-small cell lung cancer eligible for nivolumab treatm

105 Adults with non-small cell lung cancer followed from 30 days post-di

106 mapped by deep learning in 100 patients with non-small cell lung cancer from the TRACERx cohort(6).

107 inase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the m

108 ing of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-di

109 ndings, elevated mRNA expression of CNOT3 in non-small cell lung cancer in comparison with the paired

110 Systemic therapy for metastatic non-small cell lung cancer is selected according to the

111 dicts disease-free survival of patients with non-small cell lung cancer more accurately than clinical

112 inhibition, 67.5%) in a xenograft syngeneic non-small cell lung cancer mouse model.

113 ated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward

114 The Cancer Genome Atlas (TCGA) datasets for non-small cell lung cancer patients also suggest an effe

115 of ATR is a promising therapy for the 10% of non-small cell lung cancer patients harboring mutations

116 Methods: Seventy-five non-small cell lung cancer patients planned for lobectom

117 FDG PET/CT radiomic signature in early-stage non-small cell lung cancer patients treated with stereot

118 ed to directly detect hsa-miR-21-5p in eight non-small cell lung cancer plasma samples.

119 Non-small cell lung cancer remains a highly lethal malig

120 Non-small cell lung cancer remains the leading cause of

121 ial with the antifibrotic drug nintedanib in non-small cell lung cancer reported clinical benefits in

122 h factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in

123 II clinical testing in ERBB2 exon 20-mutant non-small cell lung cancer resulted in a confirmed objec

124 cted from real PET/CT scans of patients with non-small cell lung cancer served as model for three 3-d

125 Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular test

126 racterized as combinational drug targets for non-small cell lung cancer treatments.

127 sociated with local control in patients with non-small cell lung cancer undergoing SBRT and could be

128 l survival rate for patients with metastatic non-small cell lung cancer was less than 5%.

129 comparative study of patients with advanced non-small cell lung cancer who received CPIs combined wi

130 Using (18)F-flortanidazole PET imaging in a non-small cell lung cancer xenograft model, we showed th

131 effect of acute metformin administration on non-small cell lung cancer xenograft tumor hypoxia using

132 five-class problem ranged between 0.64 (for non-small cell lung cancer) and 0.82 (for melanoma); all

133 ared to those with the less aggressive form (non-small cell lung cancer).

134 riance of commonly observed mutated genes in non-small cell lung cancer, and their wild-type counterp

135 P2A (SMAPs) in Burkitt lymphoma, KRAS-driven non-small cell lung cancer, and triple-negative breast c

136 alent in both adeno and squamous subtypes of non-small cell lung cancer, as well as additional tumor

137 ard of care for many malignancies, including non-small cell lung cancer, but its benefits have not ex

138 ase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic

139 Two major treatment strategies employed in non-small cell lung cancer, NSCLC, are tyrosine kinase i

140 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer.

141 with poor clinical outcome in patients with non-small cell lung cancer, particularly those with lung

142 g anti-PD-1-treated patients with metastatic non-small cell lung cancer, those with lower PD-1/PD-L1

143 PD-L1) adnectin PET tracer, in patients with non-small cell lung cancer.

144 er, pancreatic cancer, colorectal cancer, or non-small cell lung cancer.

145 ominates the initial treatment of metastatic non-small cell lung cancer.

146 arly adenocarcinoma, a pathologic subtype of non-small cell lung cancer.

147 approximately 20% of patients with advanced non-small cell lung cancer.

148 s an unmet need in the clinical diagnosis of non-small cell lung cancer.

149 bined datasets of normal lung epithelium and non-small cell lung cancer.

150 activity in tumor tissues from patients with non-small cell lung cancer.

151 th head and neck squamous cell carcinoma and non-small cell lung cancer.

152 iferation and tumorigenicity of KEAP1-mutant non-small cell lung cancer.

153 ing that CNOT3 is required for the growth of non-small cell lung cancer.

154 ch include breast, prostate, colorectal, and non-small cell lung cancer.

155 in approximately 15% to 20% of patients with non-small cell lung cancer.

156 ized uptake value is a prognostic marker for non-small cell lung cancer.

157 verall survival for patients with metastatic non-small cell lung cancer.

158 study to explore and control for RNA-ITH in non-small cell lung cancer.

159 profiling study of 245 Chinese patients with non-small cell lung cancer.

160 gnosis of pulmonary nodules in patients with non-small cell lung cancer.

161 r (SqCLC), the second most common subtype of non-small cell lung cancer.

162 g the evaluation of lung nodules and stage I non-small cell lung cancer.

163 orthotopic immunocompetent murine models of non-small cell lung cancer: CMT167 (CMT) and Lewis lung

164 ly silenced by promoter methylation in human non-small cell lung cancers (NSCLC) harboring mutations

165 omplexes, occurs at very high frequencies in non-small cell lung cancers (NSCLC).

166 cation, is elevated in both human and murine non-small cell lung cancers (NSCLC).

167 R (epidermal growth factor receptor) -mutant non-small cell lung cancers (NSCLCs) undergo transformat

168 specific mutations characteristic of nearby non-small cell lung cancers (NSCLCs).

169 we analysed the prognostic value of SASH1 in non-small cell lung cancers using publicly available dat

170 er of regulatory sites within the genomes of non-small cell lung cancers with a global scan for open

171 ed as a first-line drug for cancers, such as non-small cell lung carcinoma (NSCLC) and bladder cancer

172 nts (34 male, 16 female, median age 73) with non-small cell lung carcinoma (NSCLC) and treated with I

173 Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated

174 y integrated platform to detect and quantify non-small cell lung carcinoma (NSCLC) rare genetic mutan

175 A (HSP70) family, are often overexpressed in non-small cell lung carcinoma (NSCLC).

176 (34 men and 16 women; median age, 73 y) with non-small cell lung carcinoma treated with ICIs were pro

177 gnant human tumors, including small-cell and non-small cell lung carcinomas, glioma, neuroblastoma, a

178 activity than 10 mg/kg of docetaxel in A549 non-small cell lung, as well as MDA-MB-436 and SUM149 tr

179 nt or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were

180 l junction adenocarcinoma (cohorts A and B), non-small-cell lung cancer (cohort C), or urothelial car

181 nhibitors for oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by

182 atients with a confirmed diagnosis of either non-small-cell lung cancer (n=442) or small-cell lung ca

183 dermal growth factor receptor ( EGFR)-mutant non-small-cell lung cancer (NSCLC) and can mediate prima

184 r is made up of distinct subtypes, including non-small-cell lung cancer (NSCLC) and small-cell lung c

185 Patients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk

186 The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against

187 of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-

188 in patients with treatment-naive EGFR-mutant non-small-cell lung cancer (NSCLC) by preventing or dela

189 The majority of non-small-cell lung cancer (NSCLC) cases are diagnosed a

190 ions and selected resynthesized compounds in non-small-cell lung cancer (NSCLC) cells showed that cyt

191 ere, using a proteomics-mediated approach in non-small-cell lung cancer (NSCLC) cells, we identified

192 t pool of ECT2 localizes to the nucleolus of non-small-cell lung cancer (NSCLC) cells, where it binds

193 -cell specific function in regulating CME in non-small-cell lung cancer (NSCLC) cells.

194 Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly be

195 e management of patients with advanced-stage non-small-cell lung cancer (NSCLC) in light of the ever-

196 first-line therapy for EGFR-mutant advanced non-small-cell lung cancer (NSCLC) is an epidermal growt

197 and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by precl

198 Non-small-cell lung cancer (NSCLC) is terminal in most p

199 genomic and transcriptomic heterogeneity in non-small-cell lung cancer (NSCLC) not only between tumo

200 se 2 trial of pembrolizumab in patients with non-small-cell lung cancer (NSCLC) or melanoma with untr

201 Patients with metastatic non-small-cell lung cancer (NSCLC) or mismatch repair de

202 EGFR-mutant non-small-cell lung cancer (NSCLC) patients inevitably d

203 on tomography (FDG-PET) response criteria in non-small-cell lung cancer (NSCLC) patients.

204 Non-small-cell lung cancer (NSCLC) represents approximat

205 new disease in patients with oligometastatic non-small-cell lung cancer (NSCLC) that did not progress

206 sociated with poor outcomes in patients with non-small-cell lung cancer (NSCLC) treated with programm

207 proximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery w

208 systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver altera

209 head and neck squamous-cell cancer (HNSCC), non-small-cell lung cancer (NSCLC), and other solid tumo

210 an alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic a

211 idermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC), failure of EGFR TKIs

212 of ensartinib in ALK-positive patients with non-small-cell lung cancer (NSCLC), in whom crizotinib t

213 noma of the head and neck (SCCHN), melanoma, non-small-cell lung cancer (NSCLC), or urothelial cancer

214 In non-small-cell lung cancer (NSCLC), the functions of OPN

215 or (EGFR) inhibitors in advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant e

216 ant regulator of acquired chemoresistance in non-small-cell lung cancer (NSCLC).

217 ogenic drivers of various cancers, including non-small-cell lung cancer (NSCLC).

218 ce to oxidative stress in vitro and in human non-small-cell lung cancer (NSCLC).

219 has an important role in the development of non-small-cell lung cancer (NSCLC).

220 hed light on the role of the NF-kappaBeta in non-small-cell lung cancer (NSCLC).

221 maintenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC).

222 in patients with previously treated advanced non-small-cell lung cancer (NSCLC).

223 oracoscopic (VATS) lobectomy for early stage non-small-cell lung cancer (NSCLC).

224 first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC).

225 editing drive extensive heterogeneity within non-small-cell lung cancer (NSCLC).

226 ined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC).

227 compounds that inhibit the proliferation of non-small-cell lung cancer (NSCLC).

228 ajor obstacle to the successful treatment of non-small-cell lung cancer (NSCLC).

229 mal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC).

230 a and myocardial infarction in patients with non-small-cell lung cancer (two [7%] of 27 patients), an

231 ia were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung canc

232 survival in patients with previously treated non-small-cell lung cancer and also showed clinical bene

233 eractions and therapeutic vulnerabilities of non-small-cell lung cancer and assess the challenges and

234 tment of patients with stage IV non-squamous non-small-cell lung cancer and no ALK or EGFR mutations.

235 ented expanding to all histological types of non-small-cell lung cancer and to add focus on immunothe

236 ee lines of previous therapy (for those with non-small-cell lung cancer and urothelial carcinoma) tha

237 ing glucose consumption and use it to screen non-small-cell lung cancer cell lines against bioactive

238 Transformed non-small-cell lung cancer cells, which maintain high gl

239 nd previously treated patients with advanced non-small-cell lung cancer expressing PD-L1.

240 lls from chemotherapy-naive individuals with non-small-cell lung cancer identified the transcription

241 measure mitochondrial membrane potential in non-small-cell lung cancer in vivo using a voltage-sensi

242 idermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in

243 xamination of the AR RTK fusion landscape in non-small-cell lung cancer is lacking.

244 f 100 clear-cell renal cell carcinoma and 99 non-small-cell lung cancer patients and identify both co

245 ll RNA sequencing (scRNA-seq) to map TIMs in non-small-cell lung cancer patients.

246 Approximately 25% of all patients with non-small-cell lung cancer present with resectable stage

247 stro-oesophageal junction adenocarcinoma and non-small-cell lung cancer were also enrolled (in two ad

248 lorectal cancer were excluded; patients with non-small-cell lung cancer were later excluded in an ame

249 s, aged 18 years or older, with ALK-positive non-small-cell lung cancer were randomly assigned (2:1)

250 b as a first-line treatment for ALK-positive non-small-cell lung cancer with 600 mg of alectinib twic

251 rvival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligan

252 patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at ba

253 sly untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mu

254 ibitors (ICIs) hold promise in patients with non-small-cell lung cancer without druggable mutations a

255 ologically confirmed metastatic non-squamous non-small-cell lung cancer without sensitising EGFR or A

256 patients with locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or A

257 se, objective responses were 12 (43%) of 28 (non-small-cell lung cancer), three (10%) of 31 (melanoma

258 6.9 months (IQR 22.3-31.5) for patients with non-small-cell lung cancer, 33.0 months (29.2-35.1) for

259 34 (31%) of 111 patients had non-small-cell lung cancer, 37 (33%) had melanoma, and 3

260 ytologically confirmed stage IV non-squamous non-small-cell lung cancer, an Eastern Cooperative Oncol

261 nt Committee on Cancer-defined stage IB-IIIA non-small-cell lung cancer, an Eastern Cooperative Oncol

262 cogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple other cancers.

263 gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, and urothelial carcinoma.

264 uded in the basket dose-expansion cohort (12 non-small-cell lung cancer, five gynaecological malignan

265 a from (1) studies in patients with advanced non-small-cell lung cancer, FLAURA (osimertinib, n = 279

266 logically documented stage III, unresectable non-small-cell lung cancer, for which they had received

267 or older, had stage IV or recurrent squamous non-small-cell lung cancer, had previously been treated

268 he most frequently mutated version of RAS in non-small-cell lung cancer, KRAS(G12C), we have the oppo

269 gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, or urothelial carcinoma.

270 f immune checkpoint inhibitors in metastatic non-small-cell lung cancer, we designed a trial to test

271 tatic, MET-amplified, EGFR mutation-positive non-small-cell lung cancer, who had progressed on EGFR T

272 potential neoadjuvant regimen for resectable non-small-cell lung cancer, with a high proportion of pa

273 urs in approximately 5% of all patients with non-small-cell lung cancer, with a similar incidence rep

274 on brain metastases from EGFR and ALK mutant non-small-cell lung cancer.

275 with chemotherapy as first-line treatment of non-small-cell lung cancer.

276 y as a first-line treatment for ALK-positive non-small-cell lung cancer.

277 d death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer.

278 erapy, as first-line treatment of metastatic non-small-cell lung cancer.

279 hemotherapy-naive patients with non-squamous non-small-cell lung cancer.

280 ty, in patients with unresectable, stage III non-small-cell lung cancer.

281 unmet need for better therapies for squamous non-small-cell lung cancer.

282 next generation inhibitors targeting EGFR in non-small-cell lung cancer.

283 omarker-driven therapy questions in squamous non-small-cell lung cancer.

284 py for patients with metastatic non-squamous non-small-cell lung cancer.

285 amous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncol

286 exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)(1).

287 Two phase III trials in adult patients with non-small-cell lung cancers evaluating a platinum-based

288 selection pressure in early-stage, untreated non-small-cell lung cancers that produces multiple route

289 e 258 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and his

290 and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be c

291 ingle-cell RNA sequencing in human and mouse non-small-cell lung cancers, we identify a cluster of de

292 kinase inhibitor (TKI)-resistant EGFR-mutant non-small-cell lung cancers.

293 es, as it was shown for BRAF in melanoma and non-small-cell lung cancers.

294 ly for the treatment of ROS1 fusion-positive non-small-cell lung cancers; histology-agnostic approval

295 d and correlated with Akt hyperactivation in non-small-cell lung carcinoma (NSCLC), promotes tumour d

296 tin (CP) are the first-line chemotherapy for non-small-cell lung carcinoma (NSCLC).

297 or some aggressive cancers, such as advanced non-small-cell lung carcinoma, combination immunotherapi

298 tion, SIX1 and SIX2 protected RAS/P53-driven non-small-cell lung carcinomas from inflammatory cell de

299 lk cells from freshly resected human primary non-small-cell lung tumors.

300 ts with mesothelioma or ovarian, pancreatic, non-small-cell lung, and breast cancers, 1 had a complet